The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 865. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.

Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-nucleated or mature cells. The methods can also include assessing the eSTBs for coronavirus susceptible markers. Also disclosed are compositions and methods (i) for inducing the differentiation of eSTBs and mature STBs from trophoblast stem cells (TSCs), (ii) for inducing the differentiation of TSCs from EPSCs, primed and naïve stem cells, pre-implantation embryos, placental stem cells, and iPSCs, and (ii) for producing TSCs by reprogramming non-trophoblast cells. The disclosed compositions and methods can be used for producing large quantities of coronavirus particles, including human, non-human, and variant coronavirus particles for virus production, the vaccine inductry, disease modeling studies, screening and evaluation of antiviral reagents, compound candidates, testing kits, and evaluation of clinical therapies.

Nucleic acid constructs for heterologous expression of a SARS-CoV-2 antigen on the surface of a yeast cell and related polypeptides, recombinant yeast cells, vaccine compositions, oral dosage formulations, and methods of inducing antigen-specific immune response to SARS-CoV-2.

Nucleic acid constructs for heterologous expression of a SARS-CoV-2 antigen on the surface of a yeast cell and related polypeptides, recombinant yeast cells, vaccine compositions, oral dosage formulations, and methods of inducing antigen-specific immune response to SARS-CoV-2.

This invention describes a fully synthetic, long-chain nucleic acid that can be used in biotechnological manufacturing processes to produce envelope proteins, virus envelopes and fragments of virus envelopes of SARS-CoV-2 and related coronaviruses in highly purified form, which, as a vaccine protect against COVID-19 and other viral diseases

The present invention relates to vaccine and treatment of novel coronavirus (SARS-CoV-2) infection (COVID-19) in mammals. Particularly, the invention relates to coronavirus vaccine and method for preparation thereof. More particularly, the present invention discloses preparation of coronavirus vaccine comprising an inactivated, purified SARS-CoV2 as active ingredient. The present invention also discloses a method for preparation of killed-inactivated SARS-CoV-2 virus which is used as antigen in the vaccine composition. The present invention further relates to the method of antigen preparation including inactivation and purification of virus, SARS-CoV-2 vaccine preparation, composition, formulation and use of the same to elicit immune response against the SARS-CoV-2 in mammals, and it is also suitable for immunizing human subjects.

Provided are a bovine rotavirus fusion protein and calf diarrhea multivalent vaccine. The bovine rotavirus fusion protein contains a VP6 fragment, wherein the VP6 fragment contains an amino acid sequence as represented by SEQ ID NO. 4, and at least one loop region of the following (a)?(c) is substituted with an antigenic epitope derived from bovine coronavirus and/or an antigenic epitope derived from E. coli: (a) amino acid residues of sites 168-177; with an amino acid sequence as represented by SEQ ID NO. 1; (b) amino acid residues of sites 194-205; with an amino acid sequence as represented by SEQ ID NO. 2; and (a) amino acid residues of sites 296-316, with an amino acid sequence as represented by SEQ ID NO. 3, The bovine rotavirus fusion protein contains a plurality of antigenic epitopes, and can enable a host to generate a plurality of antibodies after immunizing the host.

The present invention relates to a vaccine composition comprising a host cell belonging to the genus Leishmania, wherein the host cell comprises a polynucleotide coding for at least one protein of a virus belonging to the family Coronaviridae. Furthermore, the invention relates to the medical and veterinary use of the vaccine composition and to a process for preparing the vaccine composition.

The present disclosure provides compositions and methods for use in vaccines, comprising polynucleotides encoding one or more viral antigen proteins and an enhancer protein, wherein the enhancer protein is a picornavirus leader (L) or a functional variant thereof. The compositions and methods provided herein may improve the production of functional viral-like particles (VLP).

The present invention relates to the recombinant production of a protein of interest in a prokaryotic host cell or eukaryotic host cell wherein the protein of interest is obtained in a correctly folded and stable form. The protein of interest may be a difficult-to-make polypeptide for use as a vaccine or a pharmaceutical. The protein of interest is co-expressed with or fused to a fold promoter, which may be a VHH antibody recognizing the said protein.